Goldman Sachs Group, Inc. (The) Analysts Give Sanofi SA (SAN) a €81.00 Price Target

Goldman Sachs Group, Inc. (The) Analysts Give Sanofi SA (SAN) a €81.00 Price Target

Goldman Sachs Group, Inc. (The) set a €81.00 ($87.10) price target on Sanofi SA (EPA:SAN) in a research report report published on Tuesday. The firm currently has a neutral rating on the stock.

SAN has been the topic of several other research reports. J P Morgan Chase & Co reiterated a sell rating on shares of Sanofi SA in a report on Monday, October 31st. Berenberg Bank set a €92.00 ($98.92) price target on Sanofi SA and gave the stock a buy rating in a report on Tuesday, November 1st. Morgan Stanley set a €77.00 ($82.80) price target on Sanofi SA and gave the stock a neutral rating in a report on Friday, November 4th. Jefferies Group LLC set a €76.00 ($81.72) price target on Sanofi SA and gave the stock a neutral rating in a report on Monday, December 19th. Finally, Sanford C. Bernstein set a €75.00 ($80.65) price target on Sanofi SA and gave the stock a neutral rating in a report on Wednesday, October 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the stock. Sanofi SA has a consensus rating of Hold and a consensus price target of €83.50 ($89.78).

Sanofi SA (EPA:SAN) opened at 74.49 on Tuesday. The firm’s 50-day moving average is €25.50 and its 200 day moving average is €25.74. Sanofi SA has a one year low of €62.50 and a one year high of €79.13. The company has a market capitalization of €95.87 billion and a PE ratio of 22.86.

About Sanofi SA

Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.

Related posts

Leave a Comment